Squamous Cell Carcinoma | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Squamous Cell Carcinoma

A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX)

Sub-indication: Head and Neck Cancer

Study Type: Drug Study

Principal Investigator: Aaron Spalding, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Debiopharm International S.A

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Squamous Cell Carcinoma Clinical Trial

Schedule an Appointment